A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Parkinson's Disease

Treatments: Drug: Preladenant; Drug: Placebo tablet to match Preladenant

Study type: Interventional

Funder types: Industry

Identifiers

NCT01294800

P06402

MK-3814-026 (Other Identifier)

Details and patient eligibility

About

This study is to evaluate the efficacy of a range of preladenant doses compared with placebo in participants with moderate to severe Parkinson's disease (PD) experiencing motor fluctuations and receiving a stable dose of levodopa (L-dopa), as measured by "off" time. Participants will continue to receive their stable regimen of L-dopa plus any adjunct medications during the study as prescribed by their physician. Several classes of adjunct medications may be used, including Amantadine, anticholinergics, dopa decarboxylase inhibitors, and dopamine agonists.

Primary Hypothesis: At least the 10 mg twice daily dose of preladenant is superior to placebo as measured by the change from Baseline to Week 12 in the mean "off" time.

Enrollment: 450 patients

Sex: All

Ages: 30 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have a diagnosis of idiopathic PD based on the United Kingdom Parkinson's Disease Society Brain Bank Criteria, judged to be moderate to severe
• Must have received prior therapy with L-dopa for more than 1 year before Screening
• Must have been on a stable, optimal dopaminergic treatment regimen, defined as maximum

therapeutic effect achieved with available anti-Parkinsonian treatment, for at least the 4 weeks immediately before randomization

• If receiving one or more of the following adjunctive treatments: amantadine, anticholinergics, catechol-O-methyltransferase inhibitors, dopa decarboxylase inhibitors, dopamine agonists, entacapone, L-dopa, must have been on a stable regimen of treatment for at least the 4 weeks immediately before randomization
• Hoehn and Yahr stage must be ≥ 2.5 and ≤ 4 following optimum titration of treatment medications at Screening
• Must be experiencing motor fluctuations with or without dyskinesias following optimum titration of

treatment medications and within the 4 weeks immediately before Screening

• Must be experiencing a minimum of 2 hours/day of "off" time as estimated by the investigator

and supported by the symptom diary (Daily Diary) at the Diary Training Visit

• With or without the help of a caregiver, must be capable of maintaining an accurate and

complete symptom diary (Daily Diary) as assessed at the Diary Training Visit

• Must have results of Screening clinical laboratory tests (complete blood count [CBC], blood

chemistries, and urinalysis) within normal limits or clinically acceptable to the investigator at Screening

• Must have results of a physical examination within normal limits or clinically acceptable limits

to the investigator

• Must be able to adhere to dose and visit schedules
• Females of child-bearing potential must have a negative serum pregnancy test (human chorionic

gonadotropin [hCG]) at Screening and must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for 2 weeks after stopping the medication

Exclusion criteria

• Must not have a form of drug-induced or atypical parkinsonism, cognitive impairment, bipolar disorder, schizophrenia, or other psychotic disorder
• Must not have had surgery for PD
• Must not have an untreated major depressive disorder meeting Diagnostic and Statistical Manual

of Mental Disorders IV Text Revision (DSM-IV-TR) criteria

• Must not be at imminent risk of self-harm or harm to others, in the investigator's opinion based on

clinical interview

• Must not have participated in any studies using preladenant
• Must not have allergy/sensitivity to preladenant or any of its excipients
• Must not have used any investigational drugs or participated in any other clinical trial within 90 days of Screening

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

450 participants in 4 patient groups, including a placebo group

Preladenant 2 mg

Experimental group

Description:

Participants will receive preladenant 2 mg taken orally twice daily (BID), one tablet in the morning and one tablet in the evening, for 12 weeks.

Treatment:

Drug: Preladenant

Preladenant 5 mg

Experimental group

Description:

Participants will receive preladenant 5 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.

Treatment:

Drug: Preladenant

Preladenant 10 mg

Experimental group

Description:

Participants will receive preladenant 10 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.

Treatment:

Drug: Preladenant

Placebo

Placebo Comparator group

Description:

Participants will receive a placebo to preladenant tablet taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.

Treatment:

Drug: Placebo tablet to match Preladenant